Altmetric – Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September

@medicaremermaid @thevindictives2 @DrEricDing Oh boy: The findings in this study are subject to at least six limitations ... Finally, these results might be susceptible to bias because of differences in testing behaviors. Not to mention self-reported vacc

RT @OlDocWheezer: @thsisbsitstinks @ScoreAndOST @JJohnsonLaw Sorry but that is just false. Not that you’ll read it but here is research sh…

@thevindictives2 @DrEricDing https://t.co/slNcbKD2Jh

@Loudoun_Lady @DrEricDing People who’ve contracted Covid initially build antibodies but they quickly decline. Also people who’ve had Covid have a 7x greater possibility of contracting myocarditis than do the vaccinated. https://t.co/slNcbKD2Jh

@Clinteroo1969 @MaximeBernier CDC says those receiving the bivalent vaccine were 84% less likely to be hospitalized than those who were unvaccinated and 73% less likely to be hospitalized than those receiving 2+ doses of the monovalent vaccine. https://t.c

@yfuruse 米国での観察研究では未接種と比較したBA.4-5対応2価ワクチンの絶対有効率は・18-49歳:43% (95%CI 39-46) ・50-64歳:28% (95%CI 22-33) ・65歳以上:22% (95%CI 15-29) お年寄にはワクチン効果が弱い😱 https://t.co/TlbOFzxQHV

@AikawaAki @mainichijpnews ワクチンの効果はお年寄りには弱い‼️ お年寄りはワクチン接種しても免疫機能が低下している😢 https://t.co/rJci9Zv8D0

@thsisbsitstinks @ScoreAndOST @JJohnsonLaw Sorry but that is just false. Not that you’ll read it but here is research showing efficacy of the bivalent booster: https://t.co/5ppTx7LuN4

31 Dec 2022

@aegisjhalmur @F8Aldzz @NateSilver538 https://t.co/FtoIcjHstH

31 Dec 2022

RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PRE…

31 Dec 2022

@AlbertSecundus @Streitschuster Was sagst du zu dieser Studie? https://t.co/1PChdKZpUL

@s_thompsett @Dcatz77 @michelleflint76 @JustinTrudeau @sciam @jeremyfaust @NebraskaMed Yeah, believe all those statements to be accurate, so we’re unlikely to find agreement here, sorry. https://t.co/dTktFmTOWk via @CDCgov

RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PRE…

RT @sailorrooscout: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PRE…

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection. Guess what? This means they PREVENTED COVID. •https://t.co/RhsS2M3dOR

@sosotakei 米国での観察研究では未接種と比較したBA.4-5対応2価ワクチンの絶対有効率は・18-49歳:43% (95%CI 39-46) ・50-64歳:28% (95%CI 22-33) ・65歳以上:22% (95%CI 15-29) お年寄にはワクチン効果が弱い✨ 日本人の方が3割程度発症予防効果が高い！😱 https://t.co/TlbOFzxQHV

@_not_sure_yet_ @abhakhazia The vaccines do stop infections and there is no evidence that re infections compound https://t.co/Drc3MZpwuZ

29 Dec 2022

@ElefantImRaum2 @MarinaDohnt Die Corona-Impfungen verringern die Ausbreitung. "bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection" https://t.co/1PChdKZpUL

29 Dec 2022

Mantenerse al día con la vacunación contra el COVID-19 es fundamental para obtener la mejor protección contra el COVID-19. Más información en https://t.co/a6tR8F9P7V https://t.co/2y000Z5H2w

#VaxFact: Staying up to date with COVID-19 vaccination is critical to getting the best protection against COVID-19. Go to https://t.co/1FoYlh56Ex https://t.co/uzOk223uxY

@real_seeking @CaryDavid722 @ptcjoneses @Kitty_Grayling @hoothathuh @nicolas_gaboury @Crazycdn2 @ShaneAKAProp @carlsmythe @Adrienn_me @dann58638436 @TakethatCt @sunshine_toes @Orwell2023 @JiminyC24 @Mattyboysmit1 @Joe09396262 @troydee @NathanaelYoung @TBD7

@5shezz4 @real_seeking @Adrienn_me @hoothathuh @nicolas_gaboury @Crazycdn2 @ShaneAKAProp @CaryDavid722 @carlsmythe @dann58638436 @TakethatCt @sunshine_toes @ptcjoneses @Orwell2023 @JiminyC24 @Kitty_Grayling @Mattyboysmit1 @Joe09396262 @troydee @NathanaelYo

@real_seeking @sunshine_toes @hoothathuh @nicolas_gaboury @Crazycdn2 @ShaneAKAProp @CaryDavid722 @carlsmythe @Adrienn_me @dann58638436 @TakethatCt @ptcjoneses @Orwell2023 @JiminyC24 @Kitty_Grayling @Mattyboysmit1 @Joe09396262 @troydee @NathanaelYoung @TBD7

@real_seeking @sunshine_toes @hoothathuh @nicolas_gaboury @Crazycdn2 @ShaneAKAProp @CaryDavid722 @carlsmythe @Adrienn_me @dann58638436 @TakethatCt @ptcjoneses @Orwell2023 @JiminyC24 @Kitty_Grayling @Mattyboysmit1 @Joe09396262 @troydee @NathanaelYoung @TBD7

@real_seeking @sunshine_toes @hoothathuh @nicolas_gaboury @Crazycdn2 @ShaneAKAProp @CaryDavid722 @carlsmythe @Adrienn_me @dann58638436 @TakethatCt @ptcjoneses @Orwell2023 @JiminyC24 @Kitty_Grayling @Mattyboysmit1 @Joe09396262 @troydee @NathanaelYoung @TBD7

@real_seeking @sunshine_toes @hoothathuh @nicolas_gaboury @Crazycdn2 @ShaneAKAProp @CaryDavid722 @carlsmythe @Adrienn_me @dann58638436 @TakethatCt @LowBudgetGenius @ptcjoneses @Orwell2023 @JiminyC24 @Kitty_Grayling @Mattyboysmit1 @Joe09396262 @troydee @Nat

RT @matthewbstoker: Important CDC study, https://t.co/GMEp3tEPbU, showing the bivalent booster decreases risk of symptomatic COVID even for…

RT @drantonioquispe: Fuentes: 1. Aprobación FDA: https://t.co/audXcfDtdv 2. Aprobación EMA: https://t.co/uJgGyWJULl 3. Eficacia de las vacu…

@Khunleng_VL @DuangritBunnag บทความอ้างอิงมาจากรายงาน Morbidity and Mortality Weekly Report ของ CDC ดูได้ที่ลิงค์ข้างล่างนะครับ ถ้าลองพยายามค้นคว้าดูบ้าง คงไม่ถามอะไรโง่ๆ ให้มันดูเหมือนฉลาดอย่างนี้ https://t.co/oMqjyK0YVQ

Fuentes: 1. Aprobación FDA: https://t.co/audXcfDtdv 2. Aprobación EMA: https://t.co/uJgGyWJULl 3. Eficacia de las vacunas bivalentes de ARNm para prevenir la infección sintomática por SARS-CoV-2: https://t.co/0yvXs3Odt7

@EdgarJo88910442 @CommieStrangler @TRyderwood @adamcarolla @Nature “Unproven”? Covid vaccines saved millions of lives. And what’s “baseless” about this data? https://t.co/dTktFmTh6M via @cdc

@yfuruse https://t.co/uhe9DxJggs https://t.co/jfPIAbOxYj 1) 検査不足による隠れコロナ死の増加（超過死亡の増減はコロナ感染者に依存）ブースター接種→易感染化→市中感染爆増（実際の数字よりさらに）→重症化予防効果を貫通 2)コロナを介しての死亡なので、ワクチンの副作用報告には反映されない。

@teru97537586 @mph_for_doctors 米国での観察研究では未接種と比較したBA.4-5対応2価ワクチンの絶対有効率は・18-49歳:43% (95%CI 39-46) ・50-64歳:28% (95%CI 22-33) ・65歳以上:22% (95%CI 15-29) お年寄にはワクチン効果が弱い✨ 日本人の方が3割程度発症予防効果が高い！ってのが医学エビデンス😱 https://t.co/TlbOFzxQHV

@partyhike ワクチン接種での年齢別の重症化や死亡防止効果は？米国での観察研究では未接種と比較したBA.4-5対応2価ワクチンの絶対有効率は・18-49歳:43% (95%CI 39-46) ・50-64歳:28% (95%CI 22-33) ・65歳以上:22% (95%CI 15-29) お年寄にはワクチン効果が弱いようだ✨ https://t.co/TlbOFzxQHV

RT @carpe_diem0820: 米国での2価ワクチンの有効性報告前回接種からの間隔の長期化で有効性↑ 重症化予防約50% Effectiveness of Bivalent mRNA Vaccines in Preventing COVID-19-Associate…

@zOjzQ8sS9mqZ5yQ 他の論文も同じ？ https://t.co/Oy8wKJoVHv https://t.co/1dQDGAbGaC サクッと検索しましたけど、2価ワクチン関連では bivalent vaccine effectivenessで引っかかる論文はあなたの示したものとCDC, PubMedに載っている2つしか見つかりませんでしたよ。他にあります？

@Daisybidulbupe @DLF_44 @LockedFab @franceinter Et une fois que tu auras lu les limites de l'étude, pointées par les auteurs, tu pourras lire celle du CDC du 02/12/22. https://t.co/RCs0ibKcSv

@RastislavCupal @D4V1D1221 @junlian_leblanc CDC:"Rappel d'ARNm bivalent offre une protection supplément.contre SRASCoV2 symptomatique chez les pers. immunocompét. qui avant, n'avaient reçu que le vacc monovalent. Les bénéfices augmentent avec le temps depu

RT @Alexander_Tin: A reminder that these rates aren't adjusted for some additional factors, like in the vaccine effectiveness estimates we…

A reminder that these rates aren't adjusted for some additional factors, like in the vaccine effectiveness estimates we saw late last month https://t.co/VQABPDyK6O

@Cailzmaster @DrAseemMalhotra https://t.co/Xp9sbpzJ0o A trials sample should be determined by the effect it is trying to quantify.

@alexmeshkin We easily could. The only problem is. Or enough people are boosting. Tweets like yours are part of the problem and could lead to many unnecessary deaths https://t.co/Drc3MZpwuZ

@ChristopheSage @Renkatroussier2 @ordre_medecins Ok bon, je demande le redoublement https://t.co/VNNCDaepKe.

@Cailzmaster @DrAseemMalhotra "8 mices"... And 800 people... And more... https://t.co/Xp9sbpzJ0o

@Cailzmaster @DrAseemMalhotra I showed you a study on a bivalent vaccine to prove its not just "mices". Because that claim was false. Here's one with both. https://t.co/Xp9sbpzJ0o

RT @ramos262740691: 【危険信号】さて、cdcが出した二価ワクのVE速報 https://t.co/haEsT9LbGx

RT @ramos262740691: 【危険信号】さて、cdcが出した二価ワクのVE速報 https://t.co/haEsT9LbGx

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

@ACMEAtomicAce @ImTracyS https://t.co/2DnaXrORSA. The study done during the time when both Delta and Omicron were the predominant variants in the country. They seem to think the numbers are sufficient and without serious side effects why wouldn't they?

@nytimes @Emily_Baum - nice article. If you do any updates to this, it would be worth memtioning the absence of clinical efficacy data when the bivalent was initially approved (interim data is now available which does show clinical efficacy) https://t.co/p

@ScottAdamsSays https://t.co/RdQv8ziZJk https://t.co/KQrlVS99GO

https://t.co/6j7gY2RWe0

@Feldmann_Klaas @zettberlin @VolkerIffland @janinisabel @destatis Direkt als Antwort darauf, wenn man weiterliest: https://t.co/PmnfEVfNrI

@BrulePhd @MagaPhoenix73 @RobSmithson6 @osmo35195362 @TastyMorsel6 @_CapitalOffense @DigiMalice @CollusionTech @AngryFleas @EducatingTrump2 @SmytheBobbi @Karlton111 @KleeOntheRight @AgainMothra @WebGuyTV @CRogers1973 @angry_mema @tip_ct @UltraGlamma @missl

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

@hypathie0104 @SncfMC @CEMizback @AfpFactuel Alors : https://t.co/ViIAEMrwm6 Bonne lecture. Article du 02/12/22.

@LittleBirbMame source: https://t.co/cVLziyWRr8

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

@Crash_the_Flash @gary20220212 @matthewbstoker @DrEricDing The bivalent vaccine is provides significant protection from infection with currently circulating Omicron variants - akin to protection afforded by the flu vaccination in an average year. https://t

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

RT @TracyBethHoeg: We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black…

We don't need more evidence we can't trust these studies' results but, in this study biv boosted less likely to be black or latino & more likely to be white. If biv boosted health status better, that could've contributed to the lower hospitalization ra

RT @Massi_Fantini84: I risultati del recente report della CDC mostrano come il booster con vaccini bivalenti forniscono una significativa p…

@GillGripper @prof_tired2 @RPur122 https://t.co/Y86fe5ZTfj

RT @MattMcGovern: Definitely get your bivalent booster because it can save your life. Also it’s 30-50% effective against getting covid in t…

Effectiveness of the U.S.-authorized bivalent mRNA booster formulations, bivalent boosters provided significant additional protection against symptomatic SARS-CoV-2 infection in persons who had previously received 2, 3, or 4 monovalent vaccine doses https:

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @Massi_Fantini84: I risultati del recente report della CDC mostrano come il booster con vaccini bivalenti forniscono una significativa p…

I risultati del recente report della CDC mostrano come il booster con vaccini bivalenti forniscono una significativa protezione contro le varianti BA.4/BA.5 di SARS-CoV-2 in persone che avevano precedentemente ricevuto 2, 3 o 4 dosi di vaccino. 4/n https:

@osmo35195362 @TastyMorsel6 @RobSmithson6 @MagaPhoenix73 @_CapitalOffense @DigiMalice @CollusionTech @AngryFleas @BrulePhd @EducatingTrump2 @SmytheBobbi @Karlton111 @KleeOntheRight @AgainMothra @WebGuyTV @CRogers1973 @angry_mema @tip_ct @UltraGlamma @missl

@TastyMorsel6 @AngryFleas @MagaPhoenix73 @_CapitalOffense @DigiMalice @CollusionTech @BrulePhd @EducatingTrump2 @SmytheBobbi @Karlton111 @KleeOntheRight @AgainMothra @WebGuyTV @CRogers1973 @angry_mema @tip_ct @UltraGlamma @missled2u @VinceGottalotta @Beast

@Bob_Wachter Boosters only reduce risk of SYMPTOMATIC infection by 50%. Since PASC/Long COVID happens as often from asymptomatic infection, what we need to know is efficacy against symptomatic *or* asymptomatic infection. That will definitely be much wo

@MitschieK And https://t.co/hsTjOgLA2c

Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 | MMWR https://t.co/WxYmOmqHh9

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

米国CDCのワクチンVEの意図的な改ざんが元データからバレてしまう https://t.co/cGUBAqcyNW

抗原原罪については https://t.co/GDUxqY5uGs https://t.co/8x3k7wxSLV https://t.co/NcrpBUsdnX https://t.co/CFEIrDmBiM ADEについては https://t.co/NUlrzymuI2 https://t.co/1Wgpi0X9yi https://t.co/yVnCVAGm0f

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @influenzer3: Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Te…

RT @roby_bhatt: 2/11 Study 1 (from early Dec): 360k outpts w/ respiratory infxn were tested for COVID (120k tested +). Those w bivalent (OG…

Definitely get your bivalent booster because it can save your life. Also it’s 30-50% effective against getting covid in the first place. But we’ll never even get close to ridding ourselves of covid if the only policy goal is 30-50% effective. https://t.co

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

@RatDarb This should answer all your questions. TLDR, getting another covid shot on a yearly basis is no different than getting your yearly Flu shot. As diseases change and grow over time, using the resources available to protect yourself and others is imp

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @carpe_diem0820: 米国での2価ワクチンの有効性報告前回接種からの間隔の長期化で有効性↑ 重症化予防約50% Effectiveness of Bivalent mRNA Vaccines in Preventing COVID-19-Associate…

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @carpe_diem0820: 米国での2価ワクチンの有効性報告前回接種からの間隔の長期化で有効性↑ 重症化予防約50% Effectiveness of Bivalent mRNA Vaccines in Preventing COVID-19-Associate…

米国での2価ワクチンの有効性報告前回接種からの間隔の長期化で有効性↑ 重症化予防約50% Effectiveness of Bivalent mRNA Vaccines in Preventing COVID-19-Associated Emergency Department or Urgent Care Encounters and Hospitalizations among Immunocompetent Adults https://t.co/OJZD7NzwrN https://t.co/8

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…

RT @j_sato: CDCの「武漢株一価💉の効果が落ちているので、オミ株二価💉を接種しよう」と呼びかける資料データから、💉の感染予防効果を算出すると・武漢株💉2回：-26% ・武漢株💉3回：-59% ・武漢株💉4回：-76% となって、💉するほど非接種者より感染しやす…